Dhitri Borah

Dhitri Borah

Auto-generated profile, based on publicly available information

Dhitri Borah

Biswanath College, Assam, India

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2024
Verified
Book Chapter
Closed access
SMSudeshna Mandal
Sudeshna Mandal
DBDhitri Borah
Dhitri Borah
DBDipjyoti Boruah
Dipjyoti Boruah
Neelesh KumarNeelesh Kumar
Neelesh Kumar
ASAvanish Kumar Shrivastav
Avanish Kumar Shrivastav
ASAmarjeet Singh
Amarjeet Singh
Secondary metabolites produced by plants are particular to their species or genus and do not contribute to the basic processes of growth, development, and reproduction. These compounds play a key role as feed deterrents against herbivores, protectants from microbial infection, abiotic stresses, UV-protectants, pollinators attractants, antioxidants, and signalling molecules. Based on their chemical structures and production routes, secondary metabolites may be further classified across several classes. Alkaloids, terpenes, and phenolic chemicals make up the largest and most common group. The importance of secondary metabolites found in plants for human nutrition has grown to be an important interesting research area. Secondary metabolites are used by people as medicine to cure illnesses and infections, flavourings, and pesticides in the recent past. Therefore, an overview of plants is provided in this chapter including secondary metabolites and how these compounds are relevant to human health.

1 May 2024
Verified
Book Chapter
Closed access
BBBarsha Baruah
Barsha Baruah
BKBobita Kumari
Bobita Kumari
AKAfsana Khatoon
Afsana Khatoon
DBDhitri Borah
Dhitri Borah
Neelesh KumarNeelesh Kumar
Neelesh Kumar
Phytomedicine refers to the use of plants to treat, diagnose and prevent diseases for thousands of years. Medicinal plants, often known as the traditional healers, are potentially rich in phytochemicals with promising pharmacological properties and therefore have been incorporated in traditional medicines. Various medicinal plants and trees are well known for their phytomedicinal benefits and are used in various drugs with lesser side effects. Active components like alkaloids, carotenoids, flavonoids, phenolic acids, tannins, proanthocyanins, sesquiterpenes, glycosides, saponins, volatile oils, minerals, etc. are present in medicinal plants. Some common medicinal plants are used widely such as Azadirachta indica (Neem), Murraya koinigii (Curry leaves), Emblica officinalis (Amla), Myrica esculenta (Kaphal, Bayberry), Terminalia bellerica (Bahera), Terminalia chebula (Haritaki), Mimosa pudica (Humble plant), and Phyllanthus niruri. In this chapter, some phytomedicinal plants and their medicinal properties as well as efficacy are reviewed and discussed.

1 March 2026 in Current Pharmaceutical Biotechnology
Verified
Journal Article
Closed access
PDF file
DBDhitri Borah
Dhitri Borah
SHSibasree Hojaisa
Sibasree Hojaisa
ISIndira Sarma
Indira Sarma
AMAnil Kumar Mavi
Anil Kumar Mavi
TSTEJVEER SINGH
TEJVEER SINGH
SMSaurabh Maru
Saurabh Maru
Cancer is a leading cause of death around the world. Cancer is still a complex disease over the years that needs to be cured. Traditional cytotoxic approaches, which have been used for years to treat neoplastic diseases, are limited due to the intricacy and low efficiency of cancer cells. Researchers are consequently pushed to seek more potent therapeutic strategies. Chimeric antigen receptor (CAR-T) cell therapy is one such innovative approach in which T lymphocytes are genetically engineered to target cancer cells. Despite the outstanding accomplishment in patients with haematological malignancies, CAR-T cell treatment has demonstrated minimal impact on solid tumors due to a number of obstacles, including proliferation, stability, trafficking, and fate within tumors. Furthermore, interactions between the host and tumour microenvironment with CAR-T cells significantly alter CAR-T cell activities. Designing and implementing these treatments additionally also requires a complex workforce. Overcoming these significant challenges, there is a requirement for innovative strategies for developing CAR-T cells with greater anti-tumor efficacy and reduced toxicity. In this review article, the current advancement in CAR-T cell technology in order to increase clinical efficacy in both solid and hematological tumors, as well as potential solutions to overcome the limitations of CAR-T cell therapy in both solid and haematological tumors.